After receiving ketamine injections, people with treatment-resistant depression displayed fewer depressive symptoms, suicidal thoughts, and anxiety, according to a research published in The Journal of Clinical Psychiatry.
Due to its dissociative effects, ketamine, an FDA-approved anaesthetic for use in hospitals, is also illegally used as a party drug. Medical professionals have seen the medicine occasionally helps those with depression for years.
424 individuals who had not fully reacted to traditional depression therapies, such as antidepressants, participated in the new trial. They started out with six ketamine infusions over the course of three weeks at Virginia clinics, according to CNN.
According to CNN, 20% of individuals who had responded by the end of six weeks said their depressive symptoms were in remission. They showed response and remission rates of 72% and 38%, respectively, after 10 infusions.
After six weeks, approximately 50% of participants who had suicidal ideation or thoughts of suicide were in remission. During the research, anxiety sufferers reported a 30% decrease in symptoms.
Suicidal ideation (SI), depression, and anxiety symptoms can all be effectively treated with ketamine. According to the researchers, "the high rates of response and remission were comparable to those for interventional treatments in population samples of TRD (treatment-resistant depression).
Jason Anthony, 52, a study participant, revealed to The Washington Post that his sadness made it difficult for him to leave his bed.
You suddenly wake up and realise something you haven't felt in fifteen years, he added.
Researchers emphasised the limitations of the study. According to CNN, the study lacked a control group, responses were self-reported, and side effects were objectively evaluated.
According to Patrick Oliver, the study's principal investigator, ketamine has the potential to aid many depressed and suicidal patients.
The epidemic of suicide has been for a very long time, according to Oliver. And we've discovered a treatment that fixes these individuals and literally only costs pennies to produce.
The FDA has approved Spravato (esketamine) nasal spray for the treatment of individuals with treatment-resistant depression when used in conjunction with an oral antidepressant. Spravato is only offered through a restricted distribution system, in accordance with a Risk Evaluation and Mitigation Strategy, due to the risk of serious adverse outcomes brought on by the sedation and dissociation caused by its administration, as well as the potential for abuse and misuse of the drug.
0 Comments
If You Have Any Doubt, Let Me Know